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Several pathways to neural cell death are involved in ischemic stroke, and all require monovalent or divalent cation influx, implicating non-
selective cation (NC) channels. NC channels are also likely to be involved in the dysfunction of vascular endothelial cells that leads to formation
of edema following cerebral ischemia. Two newly described NC channels have emerged as potential participants in ischemic stroke, the acid
sensing ion channel (ASIC), and the sulfonylurea receptor-1 (SUR1)-regulated NCCa-ATP channel. Non-specific blockers of NC channels,
including pinokalant (LOE 908 MS) and rimonabant (SR141716A), have beneficial effects in rodent models of ischemic stroke. Evidence is
accumulating that NC channels formed by members of the transient receptor potential (TRP) family are also up-regulated in ischemic stroke and
may play a direct role in calcium-mediated neuronal death. The nascent field of NC channels, including TRP channels, in ischemic stroke is poised
to provide novel mechanistic insights and therapeutic strategies for this often devastating human condition.
© 2007 Elsevier B.V. All rights reserved.Keywords: Cation channel; Acid sensing ion channel; NCCa-ATP channel; Transient receptor potential; Cerebral ischemia; Stroke1. Introduction
A number of different mechanisms have been implicated in
cell death in CNS ischemia and stroke, including excitotoxicity,
oxidative stress, apoptosis, and oncotic (necrotic) cell death.
Each of these mechanisms is thought to propagate through
largely distinct, mutually exclusive signal transduction path-
ways [1]. However, in some measure, each of these mechanisms
requires cation influx into neural cells. Unchecked influx of Na+
gives rise to oncotic cell swelling (cytotoxic edema) which
predisposes to oncotic cell death (Fig. 1). Unchecked influx of
Ca2+ can trigger apoptotic as well as necrotic death. Because
cation channels are responsible for most cation influx, it is
evident that cation channels are key to life–death processes in
neural cells during ischemic stroke.⁎ Corresponding author. Department of Neurosurgery, 22 S. Greene St., Suite
12SD, Baltimore, MD 21201-1595, USA. Tel.: +1 410 328 0850; fax: +1 410
328 0756.
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doi:10.1016/j.bbadis.2007.03.004A variety of cation channels have been implicated in neural
cell death induced by ischemia/hypoxia. Among them are
channels that are highly selective for permeant cations, such as
voltage-dependent Na+ and Ca2+ channels, as well as channels
that are not selective for any given cation — non-selective
cation (NC) channels. In ischemic stroke, much attention has
been directed to dihydropyridine-sensitive L-type voltage-
dependent Ca2+ channels (CaV1.2), but block of this channel
in patients with acute ischemic stroke has shown little benefit
[2]. Arguably, the best-studied channels in ischemic stroke
belong to the group of receptor operated cation channels opened
by glutamate, including N-methyl-D-aspartate (NMDA) and α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA)
receptor channels, which are involved in excitotoxic cell
death [3,4]. Again, however, clinical trials with agents targeting
these mechanisms have been disappointing [5–7]. Unfavorable
experiences with mechanisms involving L-type Ca2+ channels
and NMDA receptor channels have resulted in redirection of
attention to other cation channels, namely, glutamate receptor-
independent, NC channels.
Fig. 1. Schematic diagram illustrating various types of edema progressing to
hemorrhagic conversion. Normally, Na+ concentrations in serum and in
extracellular space are the same, and much higher than inside the neuron.
Cytotoxic edema of neurons is due to entry of Na+ into ischemic neurons via
pathways such as NCCa-ATP channels, depleting extracellular Na
+ and thereby
setting up a concentration gradient between intravascular and extracellular
compartments. Ionic edema results from cytotoxic edema of endothelial cells,
due to expression of cation channels on both the luminal and abluminal side,
allowing Na+ from the intravascular compartment to traverse the capillary wall
and replenish Na+ in the extracellular space. Vasogenic edema results from
degradation of tight junctions between endothelial cells, transforming capillaries
into “fenestrated” capillaries that allow extravasation (outward filtration) of
proteinatious fluid. Oncotic death of neuron is the ultimate consequence of
cytotoxic edema. Oncotic death of endothelial cells results in complete loss of
capillary integrity and in extravasation of blood. i.e., hemorrhagic conversion.
(from Simard et al. [8], with permission).
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pathophysiological processes that contribute to adverse out-
come in ischemic stroke include formation of ionic edema,
vasogenic edema and hemorrhagic conversion — all processes
involving capillary endothelial cells [8] (Fig. 1). Molecular
mechanisms involved in these processes are only beginning to
be elucidated. In the case of ionic edema formation,
transcapillary flux of Na+ constitutes the seminal process that
drives inflow of H2O into brain parenchyma, resulting in edema
and swelling. It is likely that NC channels play a crucial role in
this process. Thus, NC channels may be implicated not only in
primary neural cell death but in secondary neural cell death
caused by endothelial dysfunction.
In recent years, study of ischemia/hypoxia-induced cell
death has been dominated by discussion of apoptosis, a form of
“delayed” programmed cell death that involves transcriptional
up-regulation of death-related gene products such as caspases.However, in stroke, only a fraction of cells undergo apoptotic
death, with the majority of cells dying by oncotic/necrotic
death [9]. The lesson from studies on apoptosis is that death,
like so many other cellular events, is driven by gene expression
and synthesis of new gene products, a concept that has not
been fully embraced in studies on oncotic/necrotic death.
Comprehensive understanding of the pathophysiology of
ischemic stroke requires a focus not only on constitutively
expressed NC channels in neurons, astrocytes and endothelial
cells, but perhaps more importantly, on newly expressed NC
channels whose transcription is driven by mechanisms
involved in ischemic stroke, namely, hypoxia and oxidative
stress.
The purpose of this review is to examine evidence that NC
channels, including TRP channels, are involved in CNS
ischemia and ischemic stroke. In reviewing this literature, it
becomes apparent that for stroke, the potential contribution of
NC channels including TRP is far less well understood than for
many other normal and pathological conditions. The relative
dearth of hard data forces consideration of somewhat weaker
evidence, including indirect or suggestive data. First, we review
potential involvement of two important, recently identified NC
channels that are up-regulated in ischemic stroke, ASIC and the
SUR1-regulated NCCa-ATP channel. Next, we consider studies
using non-specific NC channel blockers, specifically pinokalant
(LOE 908 MS), the fenamates, SKF 96365 and rimonabant
(SR141716A). Finally, we consider evidence for involvement
of NC channels of the TRP family, reviewing not only data
documenting their role in neuronal death and their up-regulation
in cerebral ischemia, but also data that would predict potential
involvement based on the transcriptional drivers, hypoxia and
oxidative stress.
2. NC channels in ischemic stroke
2.1. Acid sensing ion channel (ASIC)
Acid sensing ion channels (ASIC) are not members of the
TRP family, but are included here because they are NC channels
relevant to ischemic stroke. ASIC are members of the epithelial
Na+ channel/degenerin family of ion channels, and they are
expressed throughout the mammalian nervous system [10,11].
Six different ASIC subunits have been cloned to date, which are
encoded by four genes (ASIC1–ASIC4) [12]. Members of this
supergene family are permeable to Na+(PNa/PK: 8–40) and, to a
lesser degree, to Ca2+, and they are blocked by amiloride (IC50,
0.2–10 μM).
ASIC were first described a quarter of a century ago in
sensory neurons by Krishtal and coworkers [13–15].
Recently, ASIC have enjoyed renewed interest in the context
of neural cell death and ischemic stroke. It is well known that
ischemia results in a marked reduction in tissue pH, and that
acidosis is an important determinant of neurological injury
[16,17]. Oxygen depletion necessitates a switch from aerobic
metabolism to anaerobic glycolysis, leading to generation of
lactic acid as well as protons, resulting in acidification of
tissues.
Table 1
Properties of the SUR1-regulated NCCa-ATP channel and of the TRPM4 channel
SUR1-regulated NCCa-ATP TRPM4
Channel conductance 35 pS 25 pS
Divalent cation conductivity No No
Pore radius 0.41 nm
Ca2+ activation (EC50) 0.12–1.5 μM 1.3 μM
ATP block (EC50) 0.8 μM 0.13–1.7 μM
ADP, AMP block No Yes
Voltage dependent No Yes
PIP2 activation Yes* Yes
PKC activation No* Yes
Glibenclamide block (EC50) 48 nM 10–100 μM
Data for SUR1-regulated NCCa-ATP channel are from published [25,26] and
unpublished observations (*Chen and Simard, unpublished). Data for TRPM4
channel [64,65,97,126–132] were selected to most closely approximate those of
the SUR1-regulated NCCa-ATP channel.
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stimuli. In contrast to most Ca2+-permeable neurotransmitter-
receptor channels such as nicotinic acetylcholine receptors and
glutamate receptors, which are inhibited as pH falls, ASIC are
activated as pH falls. They are generally inactivated at
physiological pH (7.4). The probability of opening of ASIC1a
increases as the pH falls below 7.0, and activation is half
maximal at a pH of 6.2— a pH range that can occur within the
penumbra and core of an infarct, especially in the context of
hyperglycemia [17]. Activation of ASIC is promoted by
stretching of the membrane, release of arachidonic acid,
production of lactate [18,19] or a drop in extracellular Ca2+
concentration [20] — conditions that occur within an infarct as
cells swell, Ca2+-dependent phospholipases are activated, and
Ca2+ influx occurs [21].
ASIC1a, the major ASIC subunit with Ca2+ permeability, is
highly expressed in neurons. Recent evidence suggests that
activation of Ca2+-permeable amiloride-sensitive ASIC1a may
be responsible for acidosis-mediated, glutamate receptor-
independent, neuronal injury [22,23]. In vitro, activation of
ASIC results in an increase in intracellular Ca2+ and induces
time-dependent neuronal injury that occurs in the presence of
the blockers of voltage-gated Ca2+ channels and glutamate
receptors.
ASIC1a may also have a role in cerebral ischemia in vivo
[22]. In rodent models of ischemic stroke, intracerebroventri-
cular administration of the ASIC1a blockers, amiloride and
tarantula toxin psalmotoxin 1 prior to onset of ischemia, as well
as knockout of the ASIC1a gene, reportedly protects from
ischemic injury [22]. Also, transient global ischemia induces
expression of ASIC2a in rat brain, including in neurons of the
hippocampus and cortex [24].
2.2. SUR1-regulated NCCa-ATP channel
The SUR1-regulated NCCa-ATP channel is a 35 pS cation
channel that conducts all inorganic monovalent cations (Na+,
K+, Cs+, Li+, Rb+), but is impermeable to Ca2+ and Mg2+ [25].
The fact that it conducts Cs+ makes it easy to distinguish from
KATP channels with which it shares several properties (see
below). Channel opening requires nanomolar concentrations of
Ca2+ on the cytoplasmic side. Channel opening is blocked by
ATP (EC50, 0.79 μM), but is unaffected by ADP or AMP.
Studies using a variety of organic monovalent cations indicate
that the channel has an equivalent pore radius of 0.41 nm
(Table 1).
The SUR1-regulated NCCa-ATP channel is believed to be
composed of pore-forming and regulatory subunits. The regu-
latory subunit is sulfonylurea receptor 1 (SUR1), the same as that
for KATP channels in pancreatic β cells [26], and so the two
channels have pharmacological profiles that resemble each other
closely. Opening of SUR1-regulated NCCa-ATP channels is
blocked by tolbutamide (EC50, 16.1 μM at pH 7.4) and
glibenclamide (EC50, 48 nM at pH 7.4). Block by sulfonylurea
is due to prolongation of and an increase in the probability of
long closed states, with no effect on open channel dwell times or
channel conductance. The potency of block by glibenclamide isincreased ∼ 8-fold at pH 6.8 (EC50, 6 nM), consistent with the
weak acid needing to enter the lipid phase of the membrane to
cause block [27]. In the presence of ATP, channel opening is
increased by diazoxide, but not pinacidil or cromakalin, as
expected for SUR1 but not SUR2. The inhibitory effect of
glibenclamide on opening of the SUR1-regulated NCCa-ATP
channel is prevented by antibody directed against one of the
cytoplasmic loops of SUR1. Knockdown of SUR1 using
antisense-oligodeoxynucleotide reduces SUR1 expression [27]
and prevents expression of functional SUR1-regulated NCCa-ATP
channels (unpublished, Simard and Chen).
The SUR1-regulated NCCa-ATP channel is not constitutively
expressed, but is expressed in the CNS under conditions of
hypoxia or injury. The channel was first discovered in freshly
isolated reactive astrocytes obtained from the hypoxic inner
zone of the gliotic capsule [25,26]. Since then, it has also been
identified in neurons from the core of an ischemic stroke [27]. In
rodent models of ischemic stroke, the SUR1 regulatory subunit
is transcriptionally up-regulated in neurons, astrocytes and
capillary endothelial cells.
The consequence of channel opening has been studied in
isolated cells that express the channel, by depleting ATP using
Na azide or Na cyanide plus 2-deoxyglucose, or by using
diazoxide. These treatments induce a strong inward current
that depolarizes the cell completely to 0 mV. Morphological
studies demonstrate that cells subsequently undergo changes
consistent with cytotoxic edema (oncotic cell swelling), with
formation of membrane blebs. Bleb formation is reproduced
without ATP depletion by diazoxide [25]. Cells later die
predominantly by non-apoptotic, propidium iodide-positive
necrotic death [27].
The effect of channel block by glibenclamide has been
studied in vitro in reactive astrocytes that express the channel
[26,27]. In cells exposed to Na azide to deplete ATP,
glibenclamide blocks membrane depolarization, significantly
reduces blebbing associated with cytotoxic edema, and
significantly reduces necrotic cell death.
The effect of channel block by glibenclamide has also been
studied in 2 rodent models of ischemic stroke [27]. Specificity
of the drug for the target was based on administering a low dose
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yield serum concentrations of ∼ 1–3 ng/ml (2–6 nM), coupled
with the low pH of the ischemic tissues, to take advantage of the
fact that glibenclamide is a weak acid that would preferentially
target acidic tissues. In a rodent model of massive ischemic
stroke with malignant cerebral edema associated with high
mortality (68%), glibenclamide reduced mortality and cerebral
edema (excess water) by half. In a rodent model of stroke
induced by thromboemboli with delayed spontaneous reperfu-
sion, glibenclamide reduced lesion volume by half, and its use
was associated with cortical sparing attributed to improved
leptomeningeal collateral blood flow due to reduced mass effect
from edema.
Recently, the outcome from stroke in humans was
retrospectively evaluated in patients with diabetes mellitus
(DM) who were taking a sulfonylurea such as glibenclamide
and who continued on it during their hospitalization for stroke
[28]. The primary outcome was a decrease in National
Institutes of Health Stroke Scale (NIHSS) of 4 points or more
from admission to discharge or a discharge NIHSS score=0.
When compared to controls (DM patients not on sulfony-
lurea), patients in the sulfonylurea group fared significantly
better, with the primary outcome being reached by 36.4% of
patients in the treatment group versus 7.1% in the control
group (p=0.007).
In summary, the salient features of the SUR1-regulated
NCCa-ATP channel are that: (i) it is not constitutively expressed,
but is transcriptionally up-regulated in association with an
hypoxic insult; (ii) when expressed, it is not active but becomes
activated when intracellular ATP is depleted, leading to cell
depolarization, cytotoxic edema and necrotic cell death; (iii)
block of the channel in vitro results in block of depolarization,
cytotoxic edema and necrotic cell death induced by ATP
depletion; (iv) block of the channel in vivo results in significant
improvement in rodent models as well as in humans with
ischemic stroke.
3. NC channel blockers in ischemic stroke
A number of studies have shown that pharmacological
inhibition of NC channels reduces focal ischemic injury in
rodent models of ischemic stroke. Although none of these
pharmacological agents is uniquely specific for any single
molecular entity, some have been shown to block TRP
channels. Because these agents are not specific, it is not
known whether the NC channel that is targeted is constitu-
tively expressed, is newly expressed by ischemia/hypoxia or
oxidative stress, or whether the drug is acting on a TRP
channel or some other NC channel. Nevertheless, such studies
provide important insights into the potential role of NC
channels in ischemic stroke, and point to the importance of
continued studies in these areas.
3.1. Pinokalant
The isoquinoline derivative pinokalant (LOE 908 MS, (R,S)-
(3,4-dihydro-6,7-dimethoxy-isoquinoline-1-yl)-2-phenyl-N,N-di[2-(2,3,4-trimethoxyphenyl)ethyl]-acetamide) blocks a vari-
ety of NC channels, including both receptor- and store-operated
NC channels that mediate Ca2+-entry, including:
(i) norepinephrine-activated Ca2+-entry channels in adrener-
gic receptor-expressing Chinese hamster ovary cells [29];
(ii) endothelin-1 (ET-1)-activated Ca2+-entry channels in rat
aorta myocytes [30], A7r5 cells [31,32], rabbit internal
carotid artery myocytes [33], in C6 glioma cells [34], in
ET-1-expressing CHO cells [35,36] and in bovine adrenal
chromaffin cells [37];
(iii) ATP- and N-formyl-L-methionyl-L-leucyl-L-phenylala-
nine (fMLP)-stimulated cation currents in HL-60 cells
[38];
(iv) vasopressin-induced cation current in A7r5 cells [39];
(v) store-operated NC channels in human endothelial cells
[40]; (however, in some cells, store-operated NC channels
are resistant to pinokalant, reflecting a significant
diversity of molecular constituents of these channels
[41,42]).
The primary candidate subunits of mammalian receptor-
and store-operated NC channels are TRP proteins. Some of
the above receptor- and store-operated NC channels that are
blocked by pinokalant have been shown to be mediated by
members of the TRP family, suggesting that pinokalant may,
at least in part, be targeting some TRP channels. Thus,
TRPC6 is an essential component of the norepinephrine-
activated channel in rabbit portal vein, and it is believed that
TRP6 plays an important role in mediating Ca2+ influx in
vascular smooth muscle [43–45]. TRPC1 has been implicated
in ET-1-evoked arterial contraction [46]. TRPC are thought to
function as Ca2+ entry channels operated by store-depletion as
well as receptor-activated channels in a variety of cell types,
including endothelial cells [47]. In the cockroach, Periplaneta
Americana, the TRPγ (pTRPγ) channel is blocked by
pinokalant [48]. However, block by pinokalant cannot be
taken as evidence in and of itself that a TRP channel is
involved in any given cationic current. Voltage-activated
delayed rectifier K+ channels in PC12 cells and cortical
neurons [49] and in HL-60 cells [38] are also blocked by
pinokalant.
Given its pharmacological profile as an inhibitor of NC
channels, pinokalant has been evaluated as a potential
neuroprotectant in rodent models of stroke [50–54].
Magnetic resonance imaging (MRI) was used to study the
effect of pinokalant in a permanent (suture occlusion) middle
cerebral artery occlusion (MCAO) model [51]. In untreated
animals, the ischemic lesion volume [defined as the region in
which the apparent diffusion coefficient (ADC) of water
decreased to below 80% of control] steadily increased by
approximately 50% during the initial 6 h of vascular occlusion.
In treated animals, the ADC lesion volume decreased by
approximately 20% during the same interval. After 6 h of
vascular occlusion, blood flow was significantly higher in
treated animals, and the volume of ATP-depleted and
morphologically injured tissue representing the infarct core
951J.M. Simard et al. / Biochimica et Biophysica Acta 1772 (2007) 947–957was 60–70% smaller. The volume of severely acidic tissue did
not differ, indicating that pinokalant does not reduce the size of
ischemic penumbra. These findings were interpreted as
demonstrating that post-occlusion treatment delays the expan-
sion of the infarct core into the penumbra for a duration of at
least 6 h.
MRI was also used to study the effect of pinokalant in a
temporary (90-min suture occlusion) MCAO model [52–54].
Before treatment, the DWI-derived infarct volume did not differ
between the groups, whereas at 4 h after MCAO, it was
significantly smaller in the treated group. A significant
difference in ischemic lesion size was detected beginning
1.5 h after treatment. The size of the ischemic core was
significantly smaller in the treatment group, while the size of the
ischemic penumbra was similar in the two groups at 85 min
after arterial occlusion. Postmortem, 2,3,5-triphenyltetrazolium
chloride (TTC)-derived infarct volume was significantly
attenuated in the pinokalant group and the neurological scores
at 24 h were significantly better among the treated rats.
3.2. Fenamates
The fenamates, flufenamic acid, mefenamic acid and
niflumic acid, block Ca2+-activated non-selective cation
channels in a variety of cells [55–57]. Flufenamic acid inhibits
several TRP members, including TRPC3 [58], TRPC5 [59,60],
TRPM2 [61–63], TRPM4 [64,65], TRPM5 [65], whereas it
increases activity of TRPC6 [66–68]. However, channels other
than TRP are also blocked by these compounds [63].
Three fenamates (flufenamic acid, meclofenamic acid and
mefenamic acid) were examined for their protective effect on
neurons under ischemic (glucose/oxygen deprivation) or
excitotoxic conditions, using the isolated retina of chick embryo
as a model [69]. The fenamates protected the retina against the
ischemic or excitotoxic insult, with only part of the neuropro-
tection attributed to inhibition of NMDA receptor-mediated
currents, implicating non-NMDA NC channels in the response.
The effect of pre-treatment or post-treatment with mefena-
mate was evaluated in a rodent model of transient focal
ischemia [70]. Neither pre-nor post-ischemic administration of a
dose previously shown effective in preventing epileptic
neuronal necrosis was found to reduce necrosis in cortex, nor
in any subcortical structures, which forced the authors to
conclude that NC channel blockade with mefenamate affords no
neuroprotection in this model.
3.3. SKF 96365
SKF 96365 (SK and F 96365) (1-(beta-[3-(4-methoxy-
phenyl)propoxy]-4-methoxyphenethyl)-1H-imidazole hydro-
chloride) is structurally distinct from the known Ca2+ antago-
nists and shows selectivity in blocking receptor-mediated Ca2+
entry, compared with receptor-mediated internal Ca2+ release
[71]. However, SKF 96365 is not as potent (IC50∼10 μM) or
selective (also inhibits voltage-gated Ca2+ entry) as would be
desirable, so caution has been advised when using this
compound [71].Measurements of intracellular Ca2+ in human embryonic
kidney (HEK)293 cells that stably expressed human TRPC3
were used to show that SKF 96365 blocks TRP channels [72].
Expression of TRPC3 in these cells forms a non-selective cation
channel that opens after the activation of phospholipase C, but
not after store depletion. Increased Ca2+ entry in TRPC3-
expressing cells is blocked by high concentrations of SKF
96365 [72].
The blood–brain barrier (BBB) serves as a critical organ in
the maintenance of CNS homeostasis and is disrupted in a
number of neurological disorders, including ischemic stroke.
SKF 96365 was used to determine if Ca2+ flux was important in
mediating hypoxic/aglycemic effects on endothelial cells of the
BBB [73–75], which do not express voltage-dependent Ca2+
channels. Expression of the tight junction protein occludin
increased after hypoxic/aglycemic stress when cells were
exposed to SKF 96365, which correlated with inhibition of
the hypoxia-induced increase in permeability. Treatment with
SKF 96365 increased intracellular Ca2+ under normoglycemic
conditions, and was protective against hypoxia-induced BBB
disruption under normoglycemia.
3.4. Other blockers — rimonabant and capsaicin
Rimonabant (SR141716A) is a compound that interacts with
the G-protein coupled cannabinoid 1 (CB1) receptor [76].
Rimonabant has also been suggested to block TRP channel
vanilloid subfamily member 1 (TRPV1) [77]. The link between
CB1 and TRPV1 is reinforced by evidence that anandamide, an
endogenous CB1 ligand, also activates TRPV1 [78]. Capsaicin
as well as H+(pH ≤ 5.9) are agonists known to activate TRPV1
[79,80].
In a rat model of ischemic stroke, rimonabant, given 30 min
after initiation of permanent MCAO, reduced infarct volume by
∼40% [81].
The effects of rimonabant and capsaicin were investigated,
with the aim of assessing the potential role of TRPV1 in a
model of global cerebral ischemia in gerbils [77,82]. Both
compounds were found to antagonize the electroencephalo-
graphic changes, hyperlocomotion and memory impairment
induced by global ischemia, and both were associated with a
progressive survival of pyramidal cells in the CA1 subfield of
the hippocampus. Notably, capsazepine, a selective TRPV1
antagonist, reversed both rimonabant-induced and capsaicin-
induced neuroprotective effects. The authors interpreted their
findings as suggesting that neuroprotection associated with
capsaicin might be attributable, at least in part, to TRPV1
desensitization.
4. TRP channels in ischemic stroke
There is a dearth of studies addressing the potential role of
TRP channels in ischemic stroke in vivo, which is attributable,
in part, to a paucity of appropriate tools. Although in vitro
studies (reviewed below) suggest a possible role, demonstrating
a role in vivo is considerably more difficult, as it requires
demonstrating the presence of one or more of the following: (i)
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gene silencing; (iii) transcriptional up-regulation under condi-
tions of hypoxia/oxidative stress in vitro; (iv) transcriptional up-
regulation under conditions of ischemic stroke in vivo.
At present, available pharmacological tools lack the required
specificity [83], and the result of silencing a single gene at a time
can be difficult to interpret, since TRP proteins tend to form
heteromultimers and can exhibit interdependent expression
[84,85]. The physical associations between TRP and other
proteins are far more complex than previously realized, and the
classical TRP proteins appear to be organized into macro-
molecular assemblies, the functions of which are only beginning
to be understood [86]. Moreover, as pointed out by Flockerzi and
colleagues [87], many of the results relating to TRP channel
activity have been obtained from experiments using hetero-
logously expressed TRP proteins and, in most cases, cells and
expression vectors optimized for over-expression of the protein
in question. Because they are purposely over-expressed, TRPs
might act in places other than the plasma membrane and they
might be forced into forming multimeric protein complexes that
do not exist in their native environment. Thus, caution is
required when extrapolating findings from in vitro experiments
to in vivo pathological conditions.
4.1. In vitro studies — TRPM2/TRPM7
Restoring extracellular Ca2+ after a period of low Ca2+
concentrations has long been known to cause a paradoxical
increase in intracellular Ca2+ levels that can lead to cell death
(‘Ca2+ paradox’). Until recently, entry of Ca2+ through NMDA
receptor channels was considered to be the major pathway
leading to the excitotoxic, delayed cell death associated with
ischemia. There is now evidence, however, that TRP channels,
specifically TRPM2 and TRPM7, may be important contribu-
tors to both the Ca2+ paradox and the delayed death of neurons
following ischemia [88–92]. Aarts and coworkers studied the
mechanism of death in cultures of mixed cortical neurons
subjected to 1.5 h of oxygen/glucose deprivation, followed by
return to normoxic conditions and treatment with an anti-
excitotoxic cocktail (MK-801, CNQX, and nimodipine) [85].
Treatment unmasked a Ca2+-mediated death mechanism
associated with a Ca2+-permeable NC conductance that was
shown to be carried by TRPM7, based on siRNA-inhibition of
TRPM7 expression. Suppressing TRPM7 expression blocked
TRPM7 currents, anoxic 45Ca2+ uptake, production of reactive
oxygen species (ROS), and anoxic death. In addition, TRPM7
suppression eliminated the need for the anti-excitotoxic cocktail
to rescue anoxic neurons and permitted the survival of neurons
previously destined to die from prolonged anoxia. Notably,
TRPM7 current is potentiated by acidosis [93], a condition that
is present with cerebral ischemia and that makes this mechanism
all the more relevant in ischemic stroke.
4.2. In vivo studies — TRPC4
Involvement of TRPC4 was studied in a rodent model of
MCAO [94]. The authors used a commercial antibody directedagainst TRPC4 (from Alamone Labs) for Western immunoblots
and immunohistochemistry. Some have cautioned that unequi-
vocal detection of endogenous TRPC4 proteins may be difficult
[87]. In any case, TRPC4 protein was found to be significantly
elevated in striatum and hippocampus 12 h–3 days after
MCAO, with TRPC4 immunoreactivity being present in
neuronal membranes.
4.3. TRPM4 — an NCCa-ATP channel
Unlike every other channel discussed so far, TRPM4 has not
been directly linked to ischemic stroke. However, it is included
here because, as first pointed out by Csanady and Adam-Vizi
[95], many of its biophysical properties are similar to those of
the SUR1-regulated NCCa-ATP channel (see Table 1), which has
been implicated in ischemic stroke (see Section 2.2). TRPM4,
together with TRPM5, are the only molecular candidates
presently known for the class of non-selective, Ca2+-imperme-
able cation channels that are activated by intracellular Ca2+ and
blocked by intracellular ATP, i.e., NCCa-ATP channels. Given
that the pore-forming subunit of the SUR1-regulated NCCa-ATP
channel has not yet been identified, it is not surprising that
speculation would arise regarding the possibility that TRPM4
(or TRPM5) might actually constitute the pore-forming subunit
of the SUR1-regulated NCCa-ATP channel.
Both the SUR1-regulated NCCa-ATP channel and TRPM4
are highly selective for monovalent cations, have no sig-
nificant permeation of Ca2+, are activated by internal Ca2+
and blocked by internal ATP. The two channels have several
features in common (Table 1), and some of the apparent
differences may be explained by straightforward arguments.
First, differences are to be expected based simply on the fact
that overexpression of TRPM4 in an artificial system may not
mimic native expression in reactive astrocytes. For example,
in native mast cells, TRPM4 activation is independent of
voltage [96] whereas expression in HEK 293 cells yields a
voltage-dependent channel whose voltage dependence is re-
moved by augmenting PIP2 [97]. Second, the lipid environ-
ment, especially membrane levels of PIP2, is known to affect
key properties of TRPM4, not only voltage dependence but
also channel kinetics and Ca2+-dependence [97]. Finally, the
high sensitivity to glibenclamide exhibited by the SUR1-
regulated NCCa-ATP channel requires co-expression with
SUR1. If SUR1 can bind to TRPM4 to increase its sensitivity
to sulfonylurea, it is not unreasonable to expect that hete-
romers of SUR1 and TRPM4 might exhibit somewhat differ-
ent properties than homomeric TRPM4.
The postulated heteromeric assembly of SUR1 and TRPM4
is further made plausible by the fact that SUR1 is known to be a
promiscuous regulatory subunit. SUR1 is best known for its role
in forming KATP channels by assembling with Kir6.1 or Kir6.2
pore forming subunits. However, heterologous constructs of
SUR1 with another inwardly rectifying K+ channel, Kir1.1a,
have also been described [98]. Speculation aside, however, it is
not yet known whether the pore forming subunit of the SUR1-
regulated NCCa-ATP channel is encoded by a gene from any
member of the TRP family.
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4.4.1. Hypoxia
Stroke is a pathological condition marked by ischemia-
induced hypoxia. Thus, we consider TRP channel expression
that is induced by hypoxia.
In pulmonary arterial smooth muscle cells, hypoxia induces a
2–3-fold increase in TRPC1 and TRPC6 mRNA and protein
levels, but has no effect on TRPC3/TRPC4 expression [99,100].
Notably, hypoxia-induced up-regulation of TRPC1 and TRPC6
is correlated with and is dependent on the transcription factor,
hypoxia inducible factor 1 (HIF-1) [99].
4.4.2. Redox state
Apart from ischemia/hypoxia, stroke is also a condition
characterized by reperfusion, which is associated with oxidant
stress. Overproduction of ROS is one of the major causes of cell
death in ischemic–reperfusion injury. ROS as well as reactive
nitrogen species (RNS) play a pivotal role in CNS pathophy-
siology, especially in the context of ischemia/reperfusion.
TRPM2, which is abundantly expressed in the brain, is a
Ca2+-permeant, non-selective cation channel that senses and
responds to oxidative stress levels in the cell. Comprehensive
reviews of the involvement of TRPM2 (a.k.a. TRPC7 or
LTRPC2) in oxidative stress-induced cell death have been
published [101–104]. TRPM2 functions as a cell death-
mediating Ca2+-permeable cation channel that possesses both
ion channel and ADP-ribose hydrolase functions. Oxidative and
nitrosative stress lead to the accumulation of cytosolic ADP-
ribose released from mitochondria, and accumulation of ADP-
ribose is required for oxidative- and nitrosative-stress-induced
gating of TRPM2 cation channels [105]. Inhibition of TRPM2
function by poly(ADP-ribose)polymerase-1 (PARP-1) inhibi-
tors protects cells from oxidative stress-induced death [102]. In
heterologous cells, TRPM2 expression enhances and TRPM2
suppression reduces vulnerability to H2O2 toxicity [106].
Although specific involvement of TRPM2 in ischemic reperfu-
sion injury in CNS has not been shown, its interdependent
expression with TRPM7, coupled with the demonstrated role of
TRPM7 in neuronal death [85], make it likely that TRPM2
indeed plays a role.Table 2
Number of consensus binding sites on promoter regions of TRPC1–7 and TRPM1–
♣ ♣ ♣ ♣ ♣
C1 C2 C3 C4 C5 C6 C7
AP-1 3 0 2 3 1 3 4
c-Myc 3 2 0 0 1 2 0
egr-1 3 2 1 4 3 4 1
HIF-1 1 1 1 0 4 2 1
NF-κB 2 3 5 4 4 4 7
PPAR α & γ 3 6 2 3 5 5 4
Sp-1 4 2 1 3 7 1 0
♣— genes with multiple transcription start sequences.
The promoter regions of 15 genes for the indicated TRP proteins were analyzed for
c-Myc, egr-1, HIF-1, NF-κB, PPAR α and γ, and Sp-1 using Gene2Promoter and M
assumed to be 2500 bp upstream and 500 bp downstream of the transcription start sTRPC channels are likely to serve as redox sensors in
vascular endothelium, where it is believed that they form the
molecular basis of endothelial oxidant-activated cation channels
[107]. TRPC are increasingly recognized for their role in
regulating endothelial barrier function [47], which in the brain,
is crucial for formation of edema in ischemic stroke [8]. In
mammalian endothelial cells, numerous TRP proteins are
expressed [108,109], including TRPC3 and TRPC4, which
associate to form heteromeric redox-sensitive cation channels in
endothelial cells [84,110]. At present, the functional role of
many endothelial TRP channels is poorly understood. Addi-
tional work will be required to advance the hypothesis that
TRPC3 and TRPC4 participate in formation of cerebral edema.
4.4.3. Analysis of promoter regions
As reviewed above, direct evidence linking TRP proteins to
ischemic stroke is limited. However, we considered that
additional insights might be gained by examining transcrip-
tional mechanisms shown to be active in ischemic stroke, and
attempting to link these mechanisms with TRP protein
expression. Cerebral ischemia is associated with hypoxia and
oxidant stress, which activate a transcriptional program in brain
that may include the transcription factors, AP-1 [111–114],
Sp-1 [27], HIF-1 [115,116], NF-κB [117,118], PPAR α and γ
[119–121], egr-1 [122,123], c-Myc [124,125].
We analyzed the promoter regions of members of the TRPC
and TRPM subfamilies, searching for consensus binding site
sequences for the transcription factors listed above. Surprisingly,
the promoter regions of all TRP proteins examined, TRPC1–7
and TRPM1–8, were found to possess multiple consensus sites
for one or more of the transcription factors linked to ischemic
stroke (Table 2). Although this analysis cannot be taken as
evidence for involvement of any of the factors in transcriptional
regulation of the TRP proteins, it indicates that none can be
excluded, suggesting that further work on the role of TRP
proteins in ischemic stroke is warranted.
5. Conclusion and Perspective
Several lines of evidence converge to support the
hypothesis that NC channels, including TRP, are involved8 for transcription factors active in ischemic stroke
♣ ♣
M1 M2 M3 M4 M5 M6 M7 M8
2 2 5 2 2 4 5 3
1 3 3 0 0 5 3 0
2 3 1 7 3 1 6 2
3 1 3 0 1 0 6 0
6 6 2 6 5 1 1 5
7 7 4 5 6 5 2 2
1 4 1 8 1 1 5 2
potential consensus sequence binding sites for the transcription factors, AP-1,
atInspector applets (www.Genomatrix.de). The promoter region analyzed was
equence.
954 J.M. Simard et al. / Biochimica et Biophysica Acta 1772 (2007) 947–957in ischemic stroke. A number of non-specific NC channel
blockers have been found to have salutary effects in cerebral
ischemia or ischemic stroke, consistent with possible
involvement of their targets, including NC and TRP channels,
in pathophysiological mechanisms of stroke. At present,
however, this line of evidence is only suggestive, and the
specific targets of these drugs remain uncertain. The
likelihood that NC channels comprised of ASIC are involved
is strong, given the prominence of acidosis in ischemic stroke,
coupled with our understanding of the activation mechanisms
for this group of channels. Similarly, the likelihood that the
SUR1-regulated NCCa-ATP channel is involved is strong, given
its profile of expression and its activation by ATP depletion.
However, further work will be required to validate this
assertion and to obtain molecular characterization of the pore-
forming component of this channel. Finally, evidence is
emerging that TRP proteins may play a direct role in ischemic
stroke, especially in Ca2+-mediated neuronal death. A
growing body of evidence suggests that the burgeoning
field of NC channels, including TRP channels, is poised to
provide novel mechanistic insights and therapeutic strategies
for ischemic stroke.
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